| | SLO | ENG | Piškotki in zasebnost

Večja pisava | Manjša pisava

Izpis gradiva Pomoč

Naslov:Prikaz raziskav bakterije Helicobacter pylori v Splošni bolnišnici Maribor od leta 1988 do 2005
Avtorji:ID Reberšek Gorišek, Jelka (Avtor)
ID Pinter, Žarko (Avtor)
ID Pocajt, Milan (Avtor)
ID Kavalar, Rajko (Avtor)
ID Novak, Dušan (Avtor)
Datoteke:URL http://www.dlib.si/details/URN:NBN:SI:doc-BCQG3DGN
 
Jezik:Slovenski jezik
Vrsta gradiva:Delo ni kategorizirano
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:UM - Univerza v Mariboru
Opis:Izhodišča. Z odkritjem bakterije Helicobacter pylori (H. pylori) v bioptičnih vzorcih želodčne sluznice in s potrditvijo njene ključne vloge pri patogenezi ulkusne bolezni dvanajstnika, želodca, gastritisa, pomembne vloge pri limfomu MALT (angl. mucosa associated lymphoid tissue) in nastanku raka želodca se je pokazala tudi možnost vzročnega zdravljenja teh pri bolezni z antimikrobnimi zdravili. Cilj antimikrobnega zdravljenja je doseči odstranitev H. pylori, zmanjšanje recidivov bolezni in zmanjšati tveganje za razvoj želodčnega raka. Okužbo s H. pylori zdravimo s kombinacijami več antimikrobnih zdravil. Naravni rezervoar okužbe za H. pylori je človeški želodec. Pri prevalenci okužbe so pomembni tudi starost bolnikov, socialno ekonomski status in bivalne razmere. Določanje protiteles razredov IgG in IgA proti H. pylori v serumu in dokazovanje antigena v blatu pri asimptomatskih bolnikih je pomembno za epidemiološke raziskave. Bolniki in metode. V raziskave so bili vključeni bolniki, rutinsko napoteni v Splošno bolnišnico Maribor (SBM) s kroničnim gastritisom in z recidivi ulkusne bolezni dvanajstnika ali želodca, v študijo o dokazovanju protiteles proti H. pylori v serumu in antigena v blatu pa asimptomatski bolniki. H. pylori smo dokazovali v bioptičnih vzorcih želodčne sluznice s histološko preiskavo, kulturo, hitrim ureaznim testom in z ugnezdeno verižno reakcijo s polimerazo (angl. nested polymerase chain reaction - nested PCR), v brisih zobnega plaka prav tako metodo PCR nested. Protimikrobno zdravljenje za izkoreninjenje H. pylori smo izvajali v 3 študijah s primerjavo 2 skupin bolnikov. Prva skupina je redno prejemala ranitidin 2 x 150 mg dnevno, v prvi študiji 3 tedne, v naslednjih študijah 8 tednov in po potrebi antacid. Druga skupina bolnikov je v prvi študiji prejela ranitidin 2 x 150 mg + eritromicin 4 x 500 mg dnevno teden dni, v drugi študiji ranitidin 2 x 150 mg + koloidni bizmutov subcitrat (KBS) 2 x 240 mg dnevno 4 tedne, v tretji študiji pa KBS 4 x 120 mg + amoksicilin 4 x 500 mg + metronidazol 4 x 500 mg dnevno 2 tedna. Z latex aglutinacijskim testom (Orion) in z encimsko imunskim testom (Virion-Serion) smo dokazovali protitelesa razredov IgG in IgA proti H. pylori v serumu in antigen v blatu (HpSA-Meridian). V protokolih o epidemioloških značilnostih H. pylori okužbe smo zbirali in analizirali podatke o starosti in spolu bolnikov, njihovih bivalnih, sanitarnih, socialnoekonomskih razmerah in šolski izobrazbi. Rezultati. Raziskave so pokazale, da je bil H. pylori najpogosteje prisoten pri ulkusni bolezni dvanajstnika in želodca. Uspešnost antimikrobnega zdravljenja in odstranitev H. pylori z ranitidinom in eritromicinom teden dni dolgo je bila 11,1 %, s kombinacijo ranitidina in KBS 4 tedne dolgo 19,04 %, s trotirno kombinacijo KBS + amoksicilin + metronidazol 2 tedna pa 92 %. H. pylori v zobnem plaku smo dokazali v 16,6 %. Za možne dejavnike tveganja za nastanek okužbe smo ovrednotili srednjo starost, slabe do srednje dobre bivalne in ekonomske razmere ter nizko do srednješolsko izobrazbo bolnikov. Pri asimptomatskih bolnikih smo dokazali protitelesa IgG pri 26/34 bolnikih, pri 1/34 so bila mejno pozitivna in negativna pri 7/34. Protitelesa IgA so bila prisotna pri 17/34, pri 6/34 mejno pozitivna in negativna pri 11/34. Pozitiven antigen v blatu je imelo 10/33 bolnikov, 23/33 pa negativen. Protitelesa IgG in IgA v serumu in antigen v blatu so bila prisotna pri 8/33 bolnikih. Zaključki. Rezultat raziskav je bil začetek iskanja H. pylori pri bolnikih z gastritisom in ulkusno boleznijo v SBM ter ugotovitev, da je najpogosteje prisoten pri ulkusni bolezni dvanajstnika in želodca. Za dokaz H. pylori smo uvedli histološko metodo, kulturo in hitri ureazni test v rutinsko klinično prakso v SBM. Pričeli smo vzročno zdravljenje gastritisa in ulkusne bolezni z antimikrobnimi zdravili in spremljali uspešnost odstranitve H. pylori in s tem povezano ozdravitev ter znižanje recidivov bolezni. Ugotovili smo, da antimikrobna občutljivost in vitro ni porok za klinično uspešnost, kar nam je pokazal rezultat zdravljenja z eritromicinom. Tudi monoterapija ni bila dovolj učinkovita. Hipoteze, da je dentalni plak lahko pomemben rezervoar okuzbe s H. pylori, nismo potrdili. Metoda PCR nested za dokaz H. pylori v bioptičnih vzorcih želodčne sluznice in brisih zobnega plaka je primer hitre in zanesljive diagnostične metode. Z analizo epidemioloških značilnosti smo ugotovili, da so možni dejavniki tveganja za nastanek H. pylori okužbe srednja starost bolnikov, slabe do srednje dobre bivalne in ekonomske razmere ter nizka do srednješolska izobrazba. Pri asimptomatskih bolnikih smo dokazali prisotnost protiteles IgG in IgA proti H. pylori v serumu ter antigena v blatu.
Leto izida:2006
Št. strani:str. II-41 - II-48
Številčenje:Letn. 75, supl. II
PID:20.500.12556/DKUM-55993 Novo okno
UDK:616.33:615.371
COBISS.SI-ID:2496575 Novo okno
ISSN pri članku:1318-0347
NUK URN:URN:SI:UM:DK:KTYPN1Z9
Datum objave v DKUM:21.12.2015
Število ogledov:2537
Število prenosov:61
Metapodatki:XML DC-XML DC-RDF
Področja:Ostalo
:
REBERŠEK GORIŠEK, Jelka, PINTER, Žarko, POCAJT, Milan, KAVALAR, Rajko in NOVAK, Dušan, 2006, Prikaz raziskav bakterije Helicobacter pylori v Splošni bolnišnici Maribor od leta 1988 do 2005. Zdravniški vestnik. glasilo Slovenskega zdravniškega društva [na spletu]. 2006. Vol. 75, no. supl. II, p. ii-41- ii–48. [Dostopano 2 april 2025]. Pridobljeno s: http://www.dlib.si/details/URN:NBN:SI:doc-BCQG3DGN
Kopiraj citat
  
Skupna ocena:
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
(0 glasov)
Vaša ocena:Ocenjevanje je dovoljeno samo prijavljenim uporabnikom.
Objavi na:Bookmark and Share


Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.

Gradivo je del revije

Naslov:Zdravniški vestnik. glasilo Slovenskega zdravniškega društva
Založnik:Slovensko zdravniško društvo
ISSN:1318-0347
COBISS.SI-ID:32893696 Novo okno

Sekundarni jezik

Jezik:Angleški jezik
Naslov:Presentation of studies on the bacterium Helicobacter pylori at Maribor teaching hospital between 1988 and 2005
Opis:Background. The discovery of the bacterium Helicobacter (H) pylori in biopsy specimens from the gastric mucosa and the confirmation of its key role in the pathogenesis of duodenal and gastric ulcer disease, and gastritis, its significant role in mucosa associated lymphoid tissue (MALT) lymphoma and in the occurrence of gastric cancer also offered the possibility of causal treatment of these diseases with antimicrobial agents. The aim of antimicrobial treatment is the eradication of H. pylori, the decrease of recurrences and lessening the risk of gastric cancer diseases. H. pylori infection is treated with a combination of several antimicrobials. The human stomach is a natural reservoir of H. pylori. In the prevalence of H. pylori infection, patient age, socio-economic status, living and sanitary conditions can play an important role. Determination of serum IgG and IgA antibodies against H. pylori and detection of the antigen in the feces of asymptomatic patients is important for epidemiologic studies. Patients and methods. The study included patients with chronic gastritis and with recurrence of duodenal and gastric ulcer disease referred routinely to Maribor Teaching Hospital (MTH) while the study on the identification of serum antibodies against H. pylori and of antigen in feces included asymptomatic patients. For confirmation of H. pylori in biopsy specimens of the gastric mucosa we used the histologic method, culture, the urease test and the nested polymerase chain reaction (nested PCR) method. The latter was also used for dental plaque smears. Antimicrobial treatment with the aim of eradicating H. pylori was carried out in three studies comparing two groups of patients: The first group always received ranitidine - 2 x 150 mg over 3 weeks in the first study and over 8 weeks in the two further studies, with an addition of antacids if needed. The second group received ranitidine 2 x 150 mg + erythromycin 4 x 500 mg for one week in the first study, ranitidine 2 x 150 mg + colloidal bismuth subcitrate (CBS) 2 x 240 mg over 4 weeks in the second study, and CBS 4 x 120 mg + amoxycillin 4 x 500 mg + metronidazole 4 x 500 mg over two weeks in the third study. With the latex agglutination and with the enzyme immune system (Virion-Serion) we identified IgG and IgA antibodies against H. pylori in serum, and antigen in feces (HpSA - Meridian). In protocols of epidemiologic characteristics of H. pylori infection we collected and analyzed the data regarding patient age and gender, living and sanitary conditions, socio-economic status and the education level. Results. The studies showed that H. pylori was most frequently present in ulcer disease of duodenum and stomach. The success of antimicrobial treatment and eradication of H. pylori with ranitidine and erythromycin over one week was 11.1 %, with the combination of ranitidine and CBS over four weeks 19.04 %, with the triple combination therapy with CBS + amoxycillin + metronidazole over two weeks 92 %. In dental plaque, H. pylori was confirmed in 16.6 %. Middle age, poor or medium living conditions and economic status, and primary to secondary education were all identified as possible risk factors for H. pylori infection. In asymptomatic patients we confirmed IgG antibodies against H. pylori in serum in 26/34, in 1/34 they were borderline positive, and negative in 7/34 patients. IgA antibodies were present in 17/34, in 6/34 they were borderline positive, and negative in 11/34. Antigen in feces was positive in 10/33 patients, negative in 23/33. Serum IgG and IgA antibodies and antigen in feces were confirmed in 8/23 patients. Conclusions. Our studies resulted in the beginning of H. pylori detection in MTH patients with gastritis and ulcer disease, and in the ascertainment that H. pylori was most frequently present in ulcer disease of stomach and duodenum. For the confirmation of H. pylori, the histologic method, culture and the urease test were introduced into routine clinical practice of MTH. Causal treatment of gastritis and ulcer disease with antimicrobials was introduced, and the success of H. pylori eradication and the decrease of recurrences was followed. We found that antimicrobial sensitivity in vitro did not warrant clinical success - a statement proved by the results of treatment with erythromycin. The effect of monotherapy was also insufficient. The hypothesis that dental plaque could be a significant reservoir of H. pylori infection was not confirmed. The nested PCR method for proof of H. pylori in gastric mucosa biopsy specimens and dental plaque smears is a rapid and reliable diagnostic method. The analysis of epidemiologic characteristics showed that risk factors for the occurrence of H. pylori infection are middle age, poor or medium living conditions and socio-economic status, and primary to secondary education. In asymptomatic patients we proved the presence of IgG and IgA antibodies, and of antigen in feces.


Komentarji

Dodaj komentar

Za komentiranje se morate prijaviti.

Komentarji (0)
0 - 0 / 0
 
Ni komentarjev!

Nazaj
Logotipi partnerjev Univerza v Mariboru Univerza v Ljubljani Univerza na Primorskem Univerza v Novi Gorici